Not applicableApproved For MarketingNCT03025360
What this trial is testing
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Who this might be right for
Tumors Harboring NTRK Fusion
Bayer
Showing 9 of 9 results